Rarely a day passes when you do not review or find out about a shop …
Read More »Eli Lilly’s Alzheimer’s Drug Good points Unanimous FDA Panel Backing
Reality checked by Nick BlackmerReality checked by Nick Blackmer Key Takeaways The FDA advisory panel unanimously endorsed donanemab, Eli Lilly’s monoclonal antibody drug for early-stage Alzheimer’s illness. Medical trials confirmed that donanemab slowed Alzheimer’s development by 29% over 18 months. To cut back the chance of mind swelling or bleeding that’s been related to the drug, Lilly says suppliers ought …
Read More »